Myelodysplastic Syndrome (MDS) Drugs Market Research Report - Global Forecast till 2030

Myelodysplastic Syndrome (MDS) Drugs Market Research Report Information by Drug Type (Chemotherapy, Immunomodulatory Drugs), Type of Syndrome (Refractory Cytopenia with Multilineage Dysplasia, Refractory Anemia, Refractory Anemia with Excess Blasts, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Multilineage Dysplasia), Route of Administration (Oral, Parenteral), End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and Region - Global Forecast till 2030

ID: MRFR/HC/6662-HCR | 90 Pages | Author: Rahul Gotadki | March 2024         

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Assumptions

2.4 Limitations

Chapter 3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

Chapter 4. Market Dynamics

4.1 Overview

4.2 Drivers

4.3 Restraints

4.4 Opportunities

4.5 Pipeline Analysis

4.5 Macroeconomic Indicators

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

Chapter 6. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type

6.1 Overview

6.2 Chemotherapy

6.2.1 Hypomethylating Drugs

6.2.1.1 Azacitidine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1.2 Decitabine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Conventional Drugs

6.2.2.1 Cytarabine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2.2 Daunorubicin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2.3 Idarubicin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Immunomodulatory Drugs

6.3.1 Lenalidomide

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.2 Thalidomide

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type of Syndrome

7.1 Overview

7.2 Refractory Anemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Refractory Anemia with Ringed Sideroblasts

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Refractory Anemia with Excess Blasts

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Refractory Cytopenia with Multilineage Dysplasia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Other

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Route of Administration

8.1 Overview

8.2 Oral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Parenteral

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Myelodysplastic Syndrome (MDS) Drugs Market, by End User

9.1 Overview

9.2 Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3 Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4 Ambulatory Surgical Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Myelodysplastic Syndrome (MDS) Drugs Market, by Region

10.1 Overview

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Overview

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12 Company Profiles

12.1 BluePoint Laboratories

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.1.6 Key Strategies

12.2 Celgene Corporation

12.3 Cipla USA Inc

12.4 Dr. Reddy's Laboratories Inc

12.5 Fosun Pharma Industrial Pte. Ltd.

12.6 Hikma Pharmaceuticals PLC

12.7 Jazz Pharmaceuticals, Inc.

12.8 Johnson & Johnson

12.9 Lupin Ltd

12.10 Otsuka America Pharmaceutical, Inc

12.11 Pfizer

12.12 Sandoz

12.13 Shilpa Medicare Limited

12.14 Sun Pharmaceutical Industries, Inc

12.15 Teva Pharmaceutical Industries Ltd

12.16 Others

Chapter 13 Appendix

LIST OF TABLES

TABLE 1. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SYNOPSIS, 2020-2027

TABLE 2. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)

TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 6. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 9. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 10. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 11. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 13. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 14. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 15. US: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 17. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 18. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 19. CANADA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 21. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 22. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 23. LATIN AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 24. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 25. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 26. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 27. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 29. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 30. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 31. WESTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 32. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 33. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 34. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 35. EASTERN EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 36. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 37. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 38. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 39. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 40. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 41. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY TYPE OF SYNDROME, 2020-2027 (USD MILLION)

TABLE 42. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 43. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1. RESEARCH PROCESS

FIGURE 2. SEGMENTATION FOR GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET

FIGURE 3. MARKET DYNAMICS FOR GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET

FIGURE 4. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY TYPE, 2020

FIGURE 5. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY TYPE OF SYNDROME, 2020

FIGURE 6. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 7. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY END USER, 2020

FIGURE 8. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY REGION, 2020

FIGURE 9. NORTH AMERICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020

FIGURE 10. EUROPE: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020

FIGURE 11. ASIA-PACIFIC: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY COUNTRY, 2020

FIGURE 12. MIDDLE EAST & AFRICA: MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SHARE, BY REGION, 2020

FIGURE 13. MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14. BLUEPOINT LABORATORIES: KEY FINANCIALS

FIGURE 15. BLUEPOINT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16. BLUEPOINT LABORATORIES: GEOGRAPHICAL REVENUE

FIGURE 17. CELGENE CORPORATION: KEY FINANCIALS

FIGURE 18. CELGENE CORPORATION: SEGMENTAL REVENUE

FIGURE 19. CELGENE CORPORATION: GEOGRAPHICAL REVENUE

FIGURE 20. CELGENE EUROPE LIMITED: KEY FINANCIALS

FIGURE 21. CELGENE EUROPE LIMITED: SEGMENTAL REVENUE

FIGURE 22. CELGENE EUROPE LIMITED: GEOGRAPHICAL REVENUE

FIGURE 23. CIPLA USA INC: KEY FINANCIALS

FIGURE 24. CIPLA USA INC: SEGMENTAL REVENUE

FIGURE 25. CIPLA USA INC: GEOGRAPHICAL REVENUE

FIGURE 26. DR. REDDY’S LABORATORIES INC: KEY FINANCIALS

FIGURE 27. DR. REDDY’S LABORATORIES INC: SEGMENTAL REVENUE

FIGURE 28. DR. REDDY’S LABORATORIES INC: GEOGRAPHICAL REVENUE

FIGURE 29. FOSUN PHARMA INDUSTRIAL PTE. LTD.: KEY FINANCIALS

FIGURE 30. FOSUN PHARMA INDUSTRIAL PTE. LTD.: SEGMENTAL REVENUE

FIGURE 31. FOSUN PHARMA INDUSTRIAL PTE. LTD.: GEOGRAPHICAL REVENUE

FIGURE 32. HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS

FIGURE 33. PHARMACEUTICALS PLC: SEGMENTAL REVENUE

FIGURE 34. HIKMA PHARMACEUTICALS PLC: GEOGRAPHICAL REVENUE

FIGURE 35. JAZZ PHARMACEUTICALS, INC: KEY FINANCIALS

FIGURE 36. JAZZ PHARMACEUTICALS, INC: SEGMENTAL REVENUE

FIGURE 37. JAZZ PHARMACEUTICALS, INC: GEOGRAPHICAL REVENUE

FIGURE 38. JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 39. JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 40. JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE

FIGURE 41. LUPIN LTD: KEY FINANCIALS

FIGURE 42. LUPIN LTD: SEGMENTAL REVENUE

FIGURE 43. LUPIN LTD: GEOGRAPHICAL REVENUE

FIGURE 44. OTSUKA AMERICA PHARMACEUTICAL, INC: KEY FINANCIALS

FIGURE 45. OTSUKA AMERICA PHARMACEUTICAL, INC: SEGMENTAL REVENUE

FIGURE 46. OTSUKA AMERICA PHARMACEUTICAL, INC: GEOGRAPHICAL REVENUE

FIGURE 47. PFIZER: KEY FINANCIALS

FIGURE 48. PFIZER: SEGMENTAL REVENUE

FIGURE 49. PFIZER: GEOGRAPHICAL REVENUE

FIGURE 50. SANDOZ: KEY FINANCIALS

FIGURE 51. SANDOZ: SEGMENTAL REVENUE

FIGURE 52. SANDOZ: GEOGRAPHICAL REVENUE

FIGURE 53. SHILPA MEDICARE LIMITED: KEY FINANCIALS

FIGURE 54. SHILPA MEDICARE LIMITED: SEGMENTAL REVENUE

FIGURE 55. SHILPA MEDICARE LIMITED: GEOGRAPHICAL REVENUE

FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES, INC: KEY FINANCIALS

FIGURE 57. SUN PHARMACEUTICAL INDUSTRIES, INC: SEGMENTAL REVENUE

FIGURE 58. SUN PHARMACEUTICAL INDUSTRIES, INC: GEOGRAPHICAL REVENUE

FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

FIGURE 60. TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL REVENUE

Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid